New Stack 1Q26 Earnings: ESTC, PATH & PD Hold the Line, but Acceleration Assumptions Remain Unproven

Core Conclusion

Elastic, UiPath, and PagerDuty avoided significant fundamental deterioration in their latest quarterly reports. Demand indicators such as cRPO acceleration and large deal counts were solid. However, the case for revenue growth re-acceleration—central to the investment thesis for all three—remains heavily debated. Elastic’s FY27 guidance explicitly embeds a sharp pickup in growth that must overcome a Q4 deceleration. UiPath’s stable execution masks a similar unresolved question on the timing and magnitude of a growth turn. PagerDuty’s setup is comparable. Until cRPO-to-revenue conversion materializes more visibly, the risk-reward on acceleration bets stays tilted to the downside.

What the Market May Be Underestimating

The market is likely discounting the quality of recent bookings signals. Elastic’s cRPO growth accelerated to 20% CC, and non-current RPO jumped 43% year-on-year with no change in discounting. The $100k+ customer cohort using AI capabilities expanded to over 600, from 470+ in Q3, now more than one-third of that group. These forward indicators suggest enterprise commitment is broadening, not shrinking. For UiPath, preliminary commentary points to stable demand and operational discipline—a foundation that could amplify upside if automation spending rebounds. The market’s focus on in-quarter revenue deceleration may underweight these leading indicators, creating a potential re-rating trigger if second-half conversion materializes.

Evidence Chain

Elastic (ESTC)
Q4 revenue of $451m (+14% CC) narrowly beat consensus, but constant-currency growth decelerated sequentially across all revenue lines. Cloud revenue of $217m (+19% CC) missed the Street’s $218m. The offset came from bookings: cRPO reached $1.20bn, total RPO $1.98bn, and non-current RPO +43% YoY. Management noted the bookings mix was tilted toward cloud commitments, particularly public-sector SIEM-as-a-Service, which generates less near-term revenue recognition than self-managed deals. AI adoption rose to 600+ $100k+ customers using AI features.

Guidance for FY27 sets revenue at $1.985–2.000bn, above consensus of $1.969bn, and implies a 260bp operating margin expansion to ~19%. It incorporates 3%/5% list price increases. Management expects Q1 to be the lowest-growth quarter and Q4 the highest, underpinned by cRPO conversion, a larger tenured salesforce, and 70% coverage of sales-led subscription revenue from existing commitments. The plan looks achievable only if cloud commitments ramp on schedule and the Q4-weighted sales execution delivers.

UiPath (PATH) and PagerDuty (PD)
Specific numbers were limited, but the round‑up characterized PATH’s results as showing stable demand and operational execution. This mirrors broader sentiment: no major deterioration, but organic growth rates continue to decline, and the acceleration narrative depends on AI‑driven platform adoption and a macro recovery that remains uncertain. PD likewise sits in a similar deceleration‑stability pattern, with the acceleration case reliant on enterprise expansion.

Key Disagreements and Risks

The core disagreement centers on whether bookings strength can overcome consumption‑driven revenue headwinds. Elastic’s guidance requires a full-year growth acceleration following Q4’s deceleration—a setup that demands near‑flawless ramp‑up of cloud commitments and no further macro softening. Any shortfall in Q2 or Q3 would rapidly undermine confidence. For PATH and PD, the risk is that stable demand does not translate into re‑accelerating growth, leaving stocks range‑bound at best. Competitive dynamics in AI‑augmented platforms and potential shifts in enterprise budget prioritization add to the uncertainty.

Valuation and Trade Implications

Elastic’s FY27 EPS guide of $3.21–3.29 and ~21.5% FCF margin top consensus, but the revenue trajectory required carries high execution risk; the analyst has placed estimates and price target under review. PATH and PD face a similar valuation conundrum—multiples have compressed, and a re‑acceleration signal would justify a repricing, while failure to inflect likely triggers further derating. The tactical stance is to wait for confirming data points: evidence that cRPO is converting into reported revenue growth, ideally by Q2/Q3, before committing to the acceleration thesis. Absent that, the “stable but not accelerating” profile keeps these names in a show‑me phase.